Iterum Therapeutics plc (Nasdaq: ITRM) ('Iterum” or the 'Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant ...

As antibiotic-resistant "superbugs" make infections trickier to treat, some in the medical community are turning to ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Researchers from the National University of Singapore (NUS) have solved a 60-year-old mystery in bacterial cell envelope ...

Microplastics aren’t just everywhere — they might be turning your dinner into a breeding ground for supercharged pathogens.

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that the United States Patent and Trademark ...

Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing ...

Dr. Jennifer Schneider discusses Centauri Therapeutics' novel approach to combating Gram-negative infections, its first ...

A brain abscess is a rare but life-threatening infection. Learn how advances in imaging, surgery, and diagnostics are ...

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens ...

Findings show imported seafood as a potential source of colistin-resistance genes, underscoring the urgency of addressing ...